Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: (1) Prenatal Aneuploidy Screening
- PMID: 33496086
- PMCID: PMC7834900
- DOI: 10.3346/jkms.2021.36.e27
Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: (1) Prenatal Aneuploidy Screening
Abstract
In 2019, the Korean Society of Maternal-Fetal Medicine developed the first Korean clinical practice guidelines for prenatal aneuploidy screening and diagnostic testing. These guidelines were developed by adapting established clinical practice guidelines in other countries that were searched systematically, and the guidelines aim to assist in decision making of healthcare providers providing prenatal care and to be used as a source for education and communication with pregnant women in Korea. This article delineates clinical practice guidelines specifically for maternal serum screening for fetal aneuploidy and cell-free DNA (cfDNA) screening. A total of 19 key questions (12 for maternal serum and 7 for cfDNA screening) were defined. The main recommendations are: 1) Pregnant women should be informed of common fetal aneuploidy that can be detected, risks for chromosomal abnormality according to the maternal age, detection rate and false positive rate for common fetal aneuploidy with each screening test, limitations, as well as the benefits and risks of invasive diagnostic testing, 2) It is ideal to give counseling about prenatal aneuploidy screening and diagnostic testing at the first prenatal visit, and counseling is recommended to be given early in pregnancy, 3) All pregnant women should be informed about maternal serum screening regardless of their age, 4) cfDNA screening can be used for the screening of trisomy 21, 18, 13 and sex-chromosome aneuploidy. It is not recommended for the screening of microdeletion, 5) The optimal timing of cfDNA screening is 10 weeks of gestation and beyond, and 6) cfDNA screening is not recommended for women with multiple gestations. The guideline was reviewed and approved by the Korean Academy of Medical Sciences.
Keywords: Aneuploidy; Cell-free DNA Screening; Down Syndrome; Korea; Maternal Serum Screening; Practice Guideline; Prenatal Diagnosis.
© 2021 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Similar articles
-
Prenatal screening for fetal aneuploidy in singleton pregnancies.J Obstet Gynaecol Can. 2011 Jul;33(7):736-750. doi: 10.1016/S1701-2163(16)34961-1. J Obstet Gynaecol Can. 2011. PMID: 21749752
-
Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: (2) Invasive Diagnostic Testing for Fetal Chromosomal Abnormalities.J Korean Med Sci. 2021 Jan 25;36(4):e26. doi: 10.3346/jkms.2021.36.e26. J Korean Med Sci. 2021. PMID: 33496085 Free PMC article.
-
Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.J Obstet Gynaecol Can. 2011 Jul;33(7):754-67. J Obstet Gynaecol Can. 2011. PMID: 21749753
-
Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies.J Obstet Gynaecol Can. 2011 Sep;33(9):955-960. doi: 10.1016/S1701-2163(16)35022-8. J Obstet Gynaecol Can. 2011. PMID: 21923994 Review.
-
Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening.Pediatr Radiol. 2018 Apr;48(4):461-470. doi: 10.1007/s00247-017-3958-y. Epub 2018 Mar 17. Pediatr Radiol. 2018. PMID: 29550862 Free PMC article. Review.
Cited by
-
Comparative analysis of obstetric, perinatal, and neurodevelopmental outcomes following chorionic villus sampling and amniocentesis.Front Med (Lausanne). 2024 Jun 28;11:1407710. doi: 10.3389/fmed.2024.1407710. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39005648 Free PMC article.
-
The implementation and impact of non-invasive prenatal testing (NIPT) for Down's syndrome into antenatal screening programmes: A systematic review and meta-analysis.PLoS One. 2024 May 16;19(5):e0298643. doi: 10.1371/journal.pone.0298643. eCollection 2024. PLoS One. 2024. PMID: 38753891 Free PMC article.
-
Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18.Sci Rep. 2022 Aug 10;12(1):13605. doi: 10.1038/s41598-022-16807-x. Sci Rep. 2022. PMID: 35948592 Free PMC article.
-
The value of combined detailed first-trimester ultrasound-biochemical analysis for screening fetal aneuploidy in the era of non-invasive prenatal testing.Arch Gynecol Obstet. 2024 Aug;310(2):843-853. doi: 10.1007/s00404-023-07267-3. Epub 2023 Nov 8. Arch Gynecol Obstet. 2024. PMID: 37938359 Free PMC article.
References
-
- KSIS. Fertility rate by maternal age (1999–2019) [Updated 2020]. [Accessed August 8, 2020]. http://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwc....
-
- Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet A. 2005;133A(1):31–36. - PubMed
-
- Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA. 1983;249(15):2034–2038. - PubMed
-
- Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams Obstetrics. 25th ed. New York, NY: McGraw-Hill Education; 2018.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical